Chronic fissures are less likely to heal with conservative measures Increase fluid and fiber ingestion Sitz baths mineral oil or stool softener Topical application of nitrates and calcium channel blockers (CCBS) Leads to sphincter relaxation, vasodilation, improved blood flow Nitrates 0.1%, 0.2%, or 0.4% glyceryl trinitrate ointment Side effects: headache (occurs in 30% of treated patients) CCBs (e.g., diltiazem, nifedipine) Similar efficacy to nitrates Better side effect profile than nitrates Topical treatment preferred over oral treatment Botulinum toxin Similar results compared to topical therapies MOA: inhibit ACh at neuromuscular junction Temporary paralysis of the anal sphincter 20 100 IU will usually result in relaxation of the anal sphincter for 3 months Side effects: increased urinary residual volume, heart block, skin irritation, allergic reactions Lateral internal sphincterotomy (LIS) Most effective therapy to heal anal fissures Sustained partial relaxation of internal anal sphincter, resulting in decreased anal sphincter tone Can be offered first-line for patients with chronic anal fissures and no fecal incontinence
This cost transparency enables consistent, predictable therapy without financial barriers to dose optimization, a critical factor in achieving target weight loss goals
The symptoms of carpal tunnel syndrome include numbness, tingling, as well as pain in the thumb and the first three fingers of the hand, pain and burning which travels up the arm, wrist pain at night which interferes with sleep, as well as weakness in the mules of the hand
Habits That Can Aggravate B12 Deficiency in Bariatric Patients After Surgery A gastric bypass surgery or any other bariatric procedure is just the first step in a patients weight loss journey
Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Structure Therapeutics Today GPCR Structure Therapeutics $48.69 -0.43 (-0.88%) As of 04:00 PM Eastern 52-Week Range $15.80 $94.90 Price Target $110.55 Shares of Structure Therapeutics NASDAQ: GPCR have far outperformed both of the companies above in the last year, rising by over 150% during that time as investors have grown enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate
